Sanofi to buy hemophilia expert Bioverativ for $11b

Jan 23, 2018

Sanofi announced its agreement to buy U.S. hemophilia specialist Bioverativ for $11.6 billion. The acquisition is seen as a way for the French health group to strengthen its presence in treatments for rare diseases. The move comes at a time of renewed interest by large drugmakers in smaller biotech firms, with Celgene announcing a $9 billion deal to buy Juno Therapeutics.

According to Reuters, analysts see the deal as expensive because of uncertainties in the hemophilia market due.

Sanofi will buy all outstanding shares of hemophilia drugmaker Bioverativ for $105 apiece in cash.

Read the Reuters report